Inovio is bringing IMMUNO-INGENUITY™ to life and is reshaping the future of treating and preventing cancer and infectious diseases.

Inovio's technology platform is capable of activating antigen-specific immune responses. With demonstrated efficacy in a Phase 2b trial, robust and targeted immune responses, a favorable safety profile, and a robust pipeline of product candidates across multiple disease states, the evidence to date is clear—Inovio is realizing the true promise of immunotherapy.